The IFNL4 ss469415590 polymorphism has recently be shown to better predict treatment response in chronic hepatitis than the IL28B rs12979860 variant. However, no data exist in patients with HIV/hepatitis C virus (HCV) coinfection. Analysing 206 HCV(+)/HIV(+) and 162 HCV(+)/HIV(−) patients, we found that compared with IL28B rs12979860, IFNL4 ss469415590 was strongly associated with response to interferon/ribavirin therapy in HCV(+)/HIV(−) individuals but not in HIV(+)/HCV(+) patients. Thus, effects of the IFNL4 variant may differ in HIV(+) and HIV(−) patients.
aDepartment of Internal Medicine I, German Center for Infection Research, University of Bonn, Bonn
bMedical Center for Infectious Diseases (MIB), Berlin
cPraxis am Ebertplatz, Cologne
dCenter for HIV and Hepatogastroenterology, Duesseldorf
eICH, Hamburg, Germany.
*Benjamin Krämer and Hans Dieter Nischalke contributed equally to the writing of this article.
Correspondence to Jacob Nattermann, MD, Department of Internal Medicine I, University of Bonn, Sigmund-Freud-Straße 25, D-53105 Bonn, Germany. Tel: +49 228 287 51416; fax: +49 228 287 51419; e-mail: email@example.com